ShareValue scores for FDC.NSE: Valuation 60, Quality 46, Growth 52, Health 51.

FDC.NSE
NSE

FDC Limited

₹370.00(-4.53%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 17%
Valuation
60
Fair Value
Price vs Value
Quality
46
Moderate
Business Strength
Growth
52
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
73
Bullish
Price Trend

Company Details

About

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026